Can you take Lutetium lu 177 vipivotide tetraxetan with Urografin 325?

The diatrizoate in Urografin 325 has a moderate potential interaction with Allergies.

Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Caution is advised on these patients. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.

The diatrizoate in Urografin 325 has a moderate potential interaction with Asthma.

Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Caution is advised on these patients. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.

lutetium Lu 177 vipivotide tetraxetan has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Lutetium Lu 177 vipivotide tetraxetan can cause severe and life-threatening myelosuppression (including anemia, thrombocytopenia, leukopenia, neutropenia); caution is recommended in at-risk patients. Complete blood counts should be performed before and during therapy.

The diatrizoate in Urografin 325 has a moderate potential interaction with Heart Failure.

Due to the transitory increase in the circulatory osmotic load, injections with urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.

lutetium Lu 177 vipivotide tetraxetan has a moderate potential interaction with Immunodeficiency.

Lutetium Lu 177 vipivotide tetraxetan can cause severe and life-threatening myelosuppression (including anemia, thrombocytopenia, leukopenia, neutropenia); caution is recommended in at-risk patients. Complete blood counts should be performed before and during therapy.

The diatrizoate in Urografin 325 has a moderate potential interaction with Multiple Myeloma.

A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma. In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death. Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors. The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules. Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.

The diatrizoate in Urografin 325 has a moderate potential interaction with Myasthenia Gravis.

The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis. Caution is advised when using these agents in patients with this condition.

The diatrizoate in Urografin 325 has a major potential interaction with Pheochromocytoma.

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.

lutetium Lu 177 vipivotide tetraxetan has a moderate potential interaction with Renal Dysfunction.

Exposure of lutetium Lu 177 vipivotide tetraxetan is expected to increase with the degree of renal dysfunction. No dose adjustment is recommended for patients with mild (baseline CrCl 60 to 89 mL/min by Cockcroft-Gault) to moderate (CrCl 30 to 59 mL/min) renal dysfunction; as these patients may be at greater risk of toxicity, renal function and adverse reactions should be monitored frequently. Pharmacokinetics and safety of lutetium Lu 177 vipivotide tetraxetan have not been studied in patients with severe (CrCl 15 to 29 mL/min) renal dysfunction or end-stage renal disease; caution is advised in these patients.